RT Journal Article
SR Electronic
T1 Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.23.20248598
DO 10.1101/2020.12.23.20248598
A1 Voloch, Carolina M
A1 Silva F, Ronaldo da
A1 de Almeida, Luiz G P
A1 Cardoso, Cynthia C
A1 Brustolini, Otavio J.
A1 Gerber, Alexandra L
A1 Guimarães, Ana Paula de C
A1 Mariani, Diana
A1 Costa, Raissa Mirella da
A1 Ferreira, Orlando C.
A1 ,
A1 ,
A1 Cavalcanti, Adriana Cony
A1 Frauches, Thiago Silva
A1 de Mello, Claudia Maria Braga
A1 Galliez, Rafael Mello
A1 Faffe, Débora Souza
A1 Castiñeiras, Terezinha M P P
A1 Tanuri, Amilcar
A1 de Vasconcelos, Ana Tereza R
YR 2020
UL http://medrxiv.org/content/early/2020/12/26/2020.12.23.20248598.abstract
AB In this study, we report the sequencing of 180 new viral genomes obtained from different municipalities of the state of Rio de Janeiro from April to December 2020. We identified a novel lineage of SARS-CoV-2, originated from B.1.1.28, distinguished by five single-nucleotide variants (SNVs): C100U, C28253U, G28628U, G28975U, and C29754U. The SNV G23012A (E484K), in the receptor-binding domain of Spike protein, was widely spread across the samples. This mutation was previously associated with escape from neutralizing antibodies against SARS-CoV-2. This novel lineage emerged in late July being first detected by us in late October and still mainly restricted to the capital of the state. However, as observed for other strains it can be rapidly spread in the state. The significant increase in the frequency of this lineage raises concerns about public health management and continuous need for genomic surveillance during the second wave of infections.Article Summary Line We identified a novel circulating lineage of SARS-CoV-2 in the state of Rio de Janeiro Brazil originated from B.1.1.28 lineage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was developed in the frameworks of Corona-omica-RJ (FAPERJ = E-26/210.179/2020) and Rede Corona-omica BR MCTI/FINEP (FINEP = 01.20.0029.000462/20, CNPq = 404096/2020-4). The study was also supported by FAPERJ E-26/010.002434/2019 and E-26/210.178/2020 and Serrapilheira Institue, Brazil for A.T, and E-26/010.002278/2019 for C.M.V. A.T.R.V. is supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq (303170/2017-4) and FAPERJ (E-26/202.903/20). R.S.F.J is a recipient of a graduate fellowship from CNPq. C.C.C is supported by FAPERJ (E-26/202.791/2019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the National Committee of Research Ethics and by the Ethics Committee from Hospital Universitario Clementino Fraga Filho (protocol numbers: 30161620.0.1001.5257 and 34025020.0.0000.5257).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes